Evidence map›Paper›PMID 34009296›Full record

ArticleNucleic acids research2021

ERG transcription factors have a splicing regulatory function involving RBFOX2 that is altered in the EWS-FLI1 oncogenic fusion.

Olivier Saulnier, Katia Guedri-Idjouadiene, Marie-Ming Aynaud, Alina Chakraborty, Jonathan Bruyr, Joséphine Pineau, Tina O'Grady, Olivier Mirabeau, Sandrine Grossetête, Bartimée Galvan and 12 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. HOX Protein Activity Regulation by Cellular Localization.Journal of developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 2 countries.

Olivier SaulnierINSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.ORCID 0000-0003-4111-1017
Katia Guedri-IdjouadieneUniversity of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
Marie-Ming AynaudINSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.
Alina ChakrabortyInstitut Curie, PSL Research University, CNRS UMR3348, INSERM U1278, F-91405 Orsay, France.
Jonathan BruyrUniversity of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
Joséphine PineauINSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.
Tina O'GradyUniversity of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.ORCID 0000-0002-1283-0293
Olivier MirabeauINSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.
Sandrine GrossetêteINSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.
Bartimée GalvanUniversity of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
Margaux ClaesUniversity of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
Zahra Al Oula HassounUniversity of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
Benjamin SadaccaINSERM U932, RT2Lab Team, Translational Research Department, PSL Research University, Institut Curie, F-75005 Paris, France.
Karine LaudINSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.
Sakina ZaïdiINSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.
Didier SurdezINSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.
Sylvain BaulandeInstitut Curie, PSL Research University, NGS Platform, 26 rue d'Ulm, F-75005 Paris, France.
Xavier RamboutUniversity of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
Franck TirodeClaude Bernard University Lyon 1, INSERM 1052, CNRS 5286, Cancer Research Center of Lyon (CRCL), Lyon University, Lyon, France.
Martin DutertreInstitut Curie, PSL Research University, CNRS UMR3348, INSERM U1278, F-91405 Orsay, France.
Olivier DelattreINSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.
Franck DequiedtUniversity of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.ORCID 0000-0003-1234-7477
Inserm · FRUniversity of Liège · BECentre National de la Recherche Scientifique · FRUniversité Claude Bernard Lyon 1 · FRUniversité Paris Sciences et Lettres · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ERG family proteins (ERG, FLI1 and FEV) are a subfamily of ETS transcription factors with key roles in physiology and development. In Ewing sarcoma, the oncogenic fusion protein EWS-FLI1 regulates both transcription and alternative splicing of pre-messenger RNAs. However, whether wild-type ERG family proteins might regulate splicing is unknown. Here, we show that wild-type ERG proteins associate with spliceosomal components, are found on nascent RNAs, and induce alternative splicing when recruited onto a reporter minigene. Transcriptomic analysis revealed that ERG and FLI1 regulate large numbers of alternative spliced exons (ASEs) enriched with RBFOX2 motifs and co-regulated by this splicing factor. ERG and FLI1 are associated with RBFOX2 via their conserved carboxy-terminal domain, which is present in EWS-FLI1. Accordingly, EWS-FLI1 is also associated with RBFOX2 and regulates ASEs enriched in RBFOX2 motifs. However, in contrast to wild-type ERG and FLI1, EWS-FLI1 often antagonizes RBFOX2 effects on exon inclusion. In particular, EWS-FLI1 reduces RBFOX2 binding to the ADD3 pre-mRNA, thus increasing its long isoform, which represses the mesenchymal phenotype of Ewing sarcoma cells. Our findings reveal a RBFOX2-mediated splicing regulatory function of wild-type ERG family proteins, that is altered in EWS-FLI1 and contributes to the Ewing sarcoma cell phenotype.

Indexed as

Alternative SplicingAdducinsCalmodulin-Binding ProteinsCell LineCell Line, TumorHeLa CellsHumansHuman Umbilical Vein Endothelial CellsOncogene Proteins, FusionProtein DomainsProto-Oncogene Protein c-fli-1Repressor ProteinsRNA-Binding Protein EWSRNA Splicing FactorsSarcoma, EwingTranscriptional Regulator ERGADD3 protein, humanAdducinsCalmodulin-Binding ProteinsERG protein, humanEWS-FLI fusion proteinFLI1 protein, humanOncogene Proteins, FusionProto-Oncogene Protein c-fli-1RBFOX2 protein, humanRepressor ProteinsRNA-Binding Protein EWSRNA Splicing FactorsTranscriptional Regulator ERG

Identifiers

PMID34009296
PMCPMC8136815
OpenAlexW3162914601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.